QLIDA Diagnostics, Inc
Transforming cardiovascular disease diagnosis and management
QLIDA, Inc. is developing novel diagnostics for cardiovascular disease diagnosis and management enabling:
• Ultrasensitive detection of cardiac biomarkers from blood
• Point of care format with 100x increased sensitivity over standard of care
• Novel biomarker platform with greater specificity and sensitivity
Other applications include clinical research and the management of chronic disease.
The QLIDA technology was developed at Drexel.